Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Clinical Study of Hemay808

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04100642
Recruitment Status : Completed
First Posted : September 24, 2019
Last Update Posted : April 27, 2020
Sponsor:
Information provided by (Responsible Party):
Tianjin Hemay Pharmaceutical Co.,Ltd

Tracking Information
First Submitted Date  ICMJE May 20, 2019
First Posted Date  ICMJE September 24, 2019
Last Update Posted Date April 27, 2020
Actual Study Start Date  ICMJE April 8, 2019
Actual Primary Completion Date October 23, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 20, 2019)
Number of adverse events and serious adverse events. [ Time Frame: Day 1 to Day 30 ]
Incidence of AEs
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 20, 2019)
  • Cmax [ Time Frame: pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose ]
    Maximum observed plasma concentration.
  • Tmax [ Time Frame: pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose ]
    Time of maximum concentration Time of maximum concentration Time of maximum concentration Time of maximum concentration Time of maximum concentration Time of maximum concentration Time of Time of maximum concentration Time of maximim plasma concentration
  • AUCt [ Time Frame: pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose ]
    Area under the plasma concentration-time curve from time zero extrapolated to infinity.
  • AUC∞ [ Time Frame: pre-dose, 0.5, 1, 2, 3, 5, 8, 12, 14, 24, 36, 48, 72 hours post-dose ]
    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase I Clinical Study of Hemay808
Official Title  ICMJE A Phase I Clinical Study Assessed the Safety Tolerance and Pharmacokinetic Characteristics of Hemay808 in Healthy Adult Volunteers
Brief Summary This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028. The safety and systemic pharmacokinetics (PK) of Hemay028 will be evaluated following topical application of Hemay808 to healthy volunteers.
Detailed Description

There are two pre-test groups. Group1 use Hemay808 and placebo on sensitive areas. Group2 will only topical use Hemay808 on 5%BSA.

After 2 pre-test group, 4 formal testing groups will start. 1% Hemay808 apply to 25%BSA; 3% Hemay808 apply to 25%BSA; 3% Hemay808 apply to 55%BSA; 7% Hemay808 apply to 25%BSA. First a single doses then wash-out for three days, after that subjects will applicant twice daily for 7 days to assess the local skin tolerability, and systemic PK of these treatments.

Approximately 42 healthy adult volunteers will be enrolled in this study with 8- 10 volunteers each cohort.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Safety Issues
Intervention  ICMJE
  • Drug: Hemay808
    topical apply
  • Drug: Placebo
    topical apply
Study Arms  ICMJE
  • Active Comparator: 1% Hemay808 apply to 25%BSA
    8 subjects use 1% Hemay808
    Intervention: Drug: Hemay808
  • Experimental: 3% Hemay808 apply to 25%BSA
    8 subjects use 3% Hemay808
    Intervention: Drug: Hemay808
  • Experimental: 3% Hemay808 apply to 55%BSA
    6 subjects use 3% Hemay808
    Intervention: Drug: Hemay808
  • Experimental: 7% Hemay808 apply to 25%BSA
    8 subjects use 7% Hemay808
    Intervention: Drug: Hemay808
  • Placebo Comparator: placebo apply to 25%BSA
    6 subjects use placebo apply to 25%BSA
    Intervention: Drug: Placebo
  • Placebo Comparator: placebo apply to 55%BSA
    2 subjects use placebo apply to 55%BSA
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 20, 2019)
42
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 22, 2019
Actual Primary Completion Date October 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Pediatric subjects aged ≥ 18 to 45 years, inclusive.
  • Male weight 50kg during screening; Female weight 45kg; Body mass index (BMI) between 19 and 24kg/m2 (including boundary value).
  • No ulceration, injury, sunburn, redness, rash, pigmentation, uneven skin color, excessive freckles or abnormal fever were found in the skin of the target coating area during screening and before administration.
  • Chinese health volunteers
  • Women of child-bearing age and all male subjects must undertake to take effective contraceptive measures during the study period and within 6 months after discontinuation of the medication.
  • All subjects will voluntarily participate in the study after knowing the content of the study and possible adverse drug reactions (ADR), and must sign the informed consent approved by the ethics committee before starting to accept any inspection specified in this study.
  • Subjects will be able to communicate well with the investigator and promise to complete the study in accordance with the study regulations.

Exclusion Criteria:

  • History of mental illness or a genetic history of mental illness, or a history of serious (5.0 NCI CTCAE 3) cardiovascular, liver, kidney, digestive tract, neurological or other diseases.
  • Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis.
  • History of atopic dermatitis.
  • History of severe (5.0 NCI CTCAE 3) skin disease.
  • Current diagnosis or history allergic disease (such as allergic nose pharynx, allergic asthma), has a history of drug allergy, always have a skin allergy (including but not limited to allergic to the patch, for metal, cosmetics and household items with contact dermatitis), known to gao min physique, or known or the judge may, the active ingredient to the study drug has allergies or accessories.
  • Regular smoking (>5 / day) or drinking (>28 units/day); Unit: 285mL beer or 25mL spirits or 100mL wine); Or drink too much tea every day (>15g tea/day); Generally, each time tea is brewed (3~5g of tea), coffee or drinks containing caffeine (>500mg/ day) (one cup of coffee contains about 85mg of caffeine).
  • Subjects were not negative by virological examination (hepatitis b surface antigen, hepatitis c antibody, human immunodeficiency virus) and gelagglutination test of treponema pallidum.
  • Common drugs (MDMA, MOR, MAMP, KETA) did not meet the requirements.
  • Have major surgery within 2 months prior to screening, or have any surgery within 4 weeks prior to screening.
  • Had treated cancer within 5 years prior to screening (except for squamous cell, basal cell, or in situ skin cancers that were cured only by cryopreservation or surgical excision).
  • History of use (including topical use) for any reason within 2 weeks prior to administration. Except the investigator determines that the drug used has a half-life of >5 years after the start of this study, the corresponding subjects can also be enrolled.
  • Have a history of drug abuse or drug abuse, or regularly (>3 times/week within 3 months before screening) use Chinese herbs, tranquilizers, sleeping pills, tranquilizers and other addictive drugs.
  • Participated in any clinical trial within 3 months prior to screening.
  • Non-physiologic blood loss 400ml (including trauma, blood collection and blood donation) within 3 months prior to screening, or blood donation during the study period or within 1 month after the study.
  • The female subjects were in lactation or pregnancy at the time of screening (meaning the serum human chorionic gonadotropin test results of female subjects of child-bearing age were higher than the reference value).
  • Female subjects with menstrual disorders for the last 2 months.
  • Female subjects of reproductive age had unprotected sex with a heterosexual partner within 14 days prior to screening.
  • Subjects of child-bearing age (male or female) plan to become pregnant during or within 6 months after the end of the study.
  • Other circumstances in which the researcher considers it inappropriate to participate in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04100642
Other Study ID Numbers  ICMJE YQ-M-18-08
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Tianjin Hemay Pharmaceutical Co.,Ltd
Study Sponsor  ICMJE Tianjin Hemay Pharmaceutical Co.,Ltd
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Tianjin Hemay Pharmaceutical Co.,Ltd
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP